G. de Castro Et Al. , "NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC," Journal of Thoracic Oncology , vol.18, no.1, pp.106-119, 2023
de Castro, G. Et Al. 2023. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology , vol.18, no.1 , 106-119.
de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., ... Cheng, Y.(2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology , vol.18, no.1, 106-119.
de Castro, Gilberto Et Al. "NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC," Journal of Thoracic Oncology , vol.18, no.1, 106-119, 2023
de Castro, Gilberto d. Et Al. "NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC." Journal of Thoracic Oncology , vol.18, no.1, pp.106-119, 2023
de Castro, G. Et Al. (2023) . "NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC." Journal of Thoracic Oncology , vol.18, no.1, pp.106-119.
@article{article, author={Gilberto de Castro Et Al. }, title={NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC}, journal={Journal of Thoracic Oncology}, year=2023, pages={106-119} }